EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor-driven stromal reprogramming in the pre-metastatic lymph node

Michelle Piquet, David A Ruddy, Viviana Cremasco, Jonathan Chang iD

F1000Research · 2025

DOI: 10.12688/f1000research.145171.3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift F1000Research, 2025. Verfasst von Michelle Piquet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Innovative Targets and Technologies, Novartis, Cambridge, MA, 02139, USA. Hauptthemen laut MEDLINE: Lymph Nodes, Stromal Cells, Cellular Reprogramming. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic dissemination is critically reliant on the formation of a receptive niche, a process which is thought to rely on signals derived from the primary tumor. Lymph nodes are continuously exposed to such signals through the flow of afferent lymph, allowing the potential reprograming of lymphoid tissue stroma in support of metastases or immunosuppression. The objective of this study was therefore to better characterize tumor-driven transcriptomic changes occurring to specific stromal populations within the tumor-draining lymph node.

Methods

We utilize single cell RNA sequencing of dissociated LN tissue extracted from tumor-bearing and naïve mice to profile the reprograming of tissue stroma within the pre-metastatic lymph node.

Results

Resulting data provides transcriptomic evidence of tumor-induced imprinting on marginal reticular cells (MRCs) and floor lymphatic endothelial cells (fLECs) populating the subcapsular sinus. These alterations appear to be unique to the tumor-draining LN and are not observed during inflammatory antigenic challenge. Notably, MRCs exhibit characteristics reminiscent of early desmoplastic CAF differentiation, fLECs engage distinct chemoattractant pathways thought to facilitate recruitment of circulating cancer cells, and both stromal populations exhibit signs of metabolic reprograming and immune-modulating potential.

Conclusions

Cumulatively, these findings build upon existing literature describing pre-metastatic niche formation and offer several promising avenues for future exploration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymph NodesStromal CellsCellular ReprogrammingAnimalsMiceLymphatic MetastasisTumor MicroenvironmentFemaleMice, Inbred C57BLTranscriptome

Stichwörter der Autor:innen

Endothelial CellFibroblastStromal CellTumor Draining Lymph Nodemetastasispre-metastatic NichescRNAseq

Autor:innen und Institutionen

  • Oncology Innovative Targets and Technologies, Novartis, Cambridge, MA, 02139, USA.
  • Oncology Translational Research, Novartis, Cambridge, MA, 02139, USA.

ORCID-Profile: Jonathan Chang

Zitieren

APA

Piquet, M., Ruddy, D. A., Cremasco, V., & Chang, J. (2025). Tumor-driven stromal reprogramming in the pre-metastatic lymph node. F1000Research. https://doi.org/10.12688/f1000research.145171.3

Vancouver

Piquet M, Ruddy DA, Cremasco V, Chang J. Tumor-driven stromal reprogramming in the pre-metastatic lymph node. F1000Research. 2025. doi:10.12688/f1000research.145171.3

BibTeX
@article{Piquet2025,
  author = {Piquet, Michelle and Ruddy, David A and Cremasco, Viviana and Chang, Jonathan},
  title = {Tumor-driven stromal reprogramming in the pre-metastatic lymph node},
  journal = {F1000Research},
  year = {2025},
  doi = {10.12688/f1000research.145171.3}
}
Kostenlos starten →